WallStSmart

Boston Scientific Corp (BSX)vsIntuit Inc (INTU)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Intuit Inc generates 0% more annual revenue ($20.12B vs $20.07B). INTU leads profitability with a 21.6% profit margin vs 14.4%. BSX appears more attractively valued with a PEG of 0.75. INTU earns a higher WallStSmart Score of 65/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

INTU

Buy

65

out of 100

Grade: C+

Growth: 6.7Profit: 8.0Value: 7.3Quality: 6.3
Piotroski: 6/9Altman Z: 2.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued
INTUSignificantly Overvalued (-308.7%)

Margin of Safety

-308.7%

Fair Value

$104.45

Current Price

$426.86

$322.41 premium

UndervaluedFair: $104.45Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

INTU5 strengths · Avg: 9.0/10
Revenue GrowthGrowth
41.0%10/10

Revenue surging 41.0% year-over-year

Market CapQuality
$120.34B9/10

Large-cap with strong market position

Return on EquityProfitability
23.5%9/10

Every $100 of equity generates 24 in profit

Profit MarginProfitability
21.6%9/10

Keeps 22 of every $100 in revenue as profit

Free Cash FlowQuality
$1.52B8/10

Generating 1.5B in free cash flow

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

INTU2 concerns · Avg: 3.0/10
P/E RatioValuation
28.1x4/10

Moderate valuation

EPS GrowthGrowth
-18.5%2/10

Earnings declined 18.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : INTU

The strongest argument for INTU centers on Revenue Growth, Market Cap, Return on Equity. Profitability is solid with margins at 21.6% and operating margin at 15.7%. Revenue growth of 41.0% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : INTU

The primary concerns for INTU are P/E Ratio, EPS Growth.

Key Dynamics to Monitor

INTU carries more volatility with a beta of 1.28 — expect wider price swings.

INTU is growing revenue faster at 41.0% — sustainability is the question.

INTU generates stronger free cash flow (1.5B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INTU scores higher overall (65/100 vs 63/100), backed by strong 21.6% margins and 41.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Intuit Inc

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Intuit Inc. is an American business that specializes in financial software. Intuit's products include the tax preparation application TurboTax, personal finance app Mint and the small business accounting program QuickBooks.

Want to dig deeper into these stocks?